Syndax Pharmaceuticals Book Value Per Share Growth & History (SNDX)
Syndax Pharmaceuticals's book value per share was $0.74 for fiscal 2025.
View full Syndax Pharmaceuticals company overviewSyndax Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.74 | -$2.62 | −78.01% |
| 2024 | 2024-12-31 | $3.36 | -$3.17 | −48.54% |
| 2023 | 2023-12-31 | $6.53 | -$0.33 | −4.80% |
| 2022 | 2022-12-31 | $6.86 | -$0.56 | −7.60% |
| 2021 | 2021-12-31 | $7.43 | $2.16 | +41.01% |
| 2020 | 2020-12-31 | $5.27 | $4.10 | +352.37% |
| 2019 | 2019-12-31 | $1.16 | -$0.97 | −45.49% |
| 2018 | 2018-12-31 | $2.14 | -$2.14 | −50.06% |
| 2017 | 2017-12-31 | $4.28 | -$0.34 | −7.41% |
| 2016 | 2016-12-31 | $4.62 | $2,958.91 | — |
| 2015 | 2015-12-31 | -$2,954.30 | -$331.98 | — |
| 2014 | 2014-12-31 | -$2,622.32 | — | — |
Syndax Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.17 | -$1.66 | −90.74% |
| Q1 2026 | 2026-03-31 | $0.47 | -$2.03 | −81.19% |
| Q4 2025 | 2025-12-31 | $0.74 | -$2.62 | −78.01% |
| Q3 2025 | 2025-09-30 | $1.33 | -$2.95 | −68.98% |
| Q2 2025 | 2025-06-30 | $1.83 | -$3.28 | −64.19% |
| Q1 2025 | 2025-03-31 | $2.50 | -$3.29 | −56.82% |
| Q4 2024 | 2024-12-31 | $3.36 | -$3.17 | −48.54% |
| Q3 2024 | 2024-09-30 | $4.28 | -$0.88 | −16.98% |
| Q2 2024 | 2024-06-30 | $5.11 | -$0.65 | −11.34% |
| Q1 2024 | 2024-03-31 | $5.79 | -$0.57 | −8.96% |
| Q4 2023 | 2023-12-31 | $6.53 | -$0.33 | −4.80% |
| Q3 2023 | 2023-09-30 | $5.16 | -$0.47 | −8.28% |
| Q2 2023 | 2023-06-30 | $5.76 | -$0.66 | −10.22% |
| Q1 2023 | 2023-03-31 | $6.36 | -$0.45 | −6.58% |
| Q4 2022 | 2022-12-31 | $6.86 | -$0.56 | −7.60% |
| Q3 2022 | 2022-09-30 | $5.62 | $1.55 | +38.04% |
| Q2 2022 | 2022-06-30 | $6.42 | $2.00 | +45.41% |
| Q1 2022 | 2022-03-31 | $6.81 | $2.08 | +43.90% |
| Q4 2021 | 2021-12-31 | $7.43 | $2.16 | +41.01% |
| Q3 2021 | 2021-09-30 | $4.07 | $0.68 | +19.87% |
| Q2 2021 | 2021-06-30 | $4.41 | $0.58 | +15.12% |
| Q1 2021 | 2021-03-31 | $4.73 | $2.96 | +167.31% |
| Q4 2020 | 2020-12-31 | $5.27 | $4.10 | +352.37% |
| Q3 2020 | 2020-09-30 | $3.40 | $1.78 | +109.42% |
| Q2 2020 | 2020-06-30 | $3.83 | $1.80 | +88.08% |
| Q1 2020 | 2020-03-31 | $1.77 | -$0.76 | −30.14% |
| Q4 2019 | 2019-12-31 | $1.16 | -$0.97 | −45.49% |
| Q3 2019 | 2019-09-30 | $1.62 | -$1.05 | −39.28% |
| Q2 2019 | 2019-06-30 | $2.04 | -$1.06 | −34.21% |
| Q1 2019 | 2019-03-31 | $2.53 | -$0.99 | −28.06% |
| Q4 2018 | 2018-12-31 | $2.14 | -$2.14 | −50.06% |
| Q3 2018 | 2018-09-30 | $2.67 | -$1.66 | −38.35% |
| Q2 2018 | 2018-06-30 | $3.10 | -$1.82 | −37.03% |
| Q1 2018 | 2018-03-31 | $3.52 | -$0.46 | −11.54% |
| Q4 2017 | 2017-12-31 | $4.28 | -$0.34 | −7.41% |
| Q3 2017 | 2017-09-30 | $4.33 | -$0.83 | −16.02% |
| Q2 2017 | 2017-06-30 | $4.92 | -$1.06 | −17.69% |
| Q1 2017 | 2017-03-31 | $3.98 | -$2.43 | −37.88% |
| Q4 2016 | 2016-12-31 | $4.62 | $2,958.91 | — |
| Q3 2016 | 2016-09-30 | $5.16 | — | — |
| Q2 2016 | 2016-06-30 | $5.98 | — | — |
| Q1 2016 | 2016-03-31 | $6.41 | — | — |
| Q4 2015 | 2015-12-31 | -$2,954.30 | — | — |
Syndax Pharmaceuticals book value per share trends
Over the last five fiscal years, Syndax Pharmaceuticals's book value per share decreased from $5.27 to $0.74, a change of -$4.53. The latest reported quarter, Q2 2026, shows $0.17.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Syndax Pharmaceuticals source filings ↗